Johnson & Johnson (JNJ) is recommended for purchase before its July 15 earnings release, with the stock up 25% year-to-date and 66% over the past year.
Finnhub07/13, 07:30 PM
Related assets
Coming up for JNJ
Explore next
Latest JNJ news
Finnhub08/27, 12:50 PM
Johnson & Johnson's autoimmune drug received FDA approval for treatment of a rare blood disease.
FirstSquawk08/08, 08:14 AM
Duato sold 41,957 J&J shares at an average price of $258.06.
FirstSquawk08/08, 08:13 AM
J&J's Duato disclosed a share sale of $1.69M at an average price of $258.74.